HEC585 trial for slowing lung scarring decline
Part of Lungs & breathing clinical trials.
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and be willing to sign the consent form and follow study visits.
- You do NOT have idiopathic pulmonary fibrosis (IPF), but you do have progressive fibrosing interstitial lung disease confirmed on chest CT.
- Despite at least 3 months of usual care, you must show recent worsening (symptoms, lung function test changes, and/or scan changes) within the past 12 months.
- Your basic lung function tests must meet limits (FEV1/FVC at least 0.7 before bronchodilators, and %FVC at least 45% predicted).
- Your DLCO (a gas-exchange test) must be between 30% and 80% of predicted.
- If you have connective-tissue disease-related lung disease, your treatment must have been stable for 12 weeks before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet, HEC585, for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the drug can help improve lung function and slow the disease. Participants must have a confirmed IPF diagnosis and meet specific breathing test results.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
This study tests an experimental medicine called HSK44459 to see if it can slow down progressive pulmonary fibrosis (PPF), a condition that causes lung scarring and breathing difficulty. The goal is to learn if the medicine can help people keep more of their lung function compared to a placebo.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This study tests an experimental pill called SYH2059 for people with IPF, a condition that causes lung scarring and makes breathing harder. The goal is to see if the pill is safe and can help slow down the disease.
Hear when a new Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.